Eligible patients* can now save up to $200.00 with the DIFICID Co-Pay Assistance Program
*Restrictions and Conditions of Use Apply
Centers for Medicare & Medicaid Services has granted a NTAP for DIFICID administered in the inpatient hospital setting to treat Clostridium difficile-associated diarrhea (CDAD)*
DIFICID Rx Assist is now available to provide reimbursement information to support patient access to DIFICID® (fidaxomicin) tablets. The reimbursement information hotline is available for patients, caregivers, physicians and healthcare provider staff to assist with reimbursement, coverage questions or patient financial support.
DIFICID® is a macrolide antibacterial drug indicated in adults ≥18 years of age for treatment of Clostridium difficile-associated diarrhea.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile.
The information provided on this Web site is intended for US healthcare professionals only.
Important Safety Information
Indications and Usage